



# Lorlatinib (Lorviqua®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » nach Vorbehandlung

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Lorlatinib, NSCLC, ALK+, previously treated .....</b>	<b>2</b>
--	----------

# Lorlatinib (Lorviqua®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » nach Vorbehandlung

**Stand:** Juli 2021

## 1 Lorlatinib, NSCLC, ALK+, previously treated

Lorlatinib, NSCLC, ALK+, previously treated																																																															
onkopedia		Facts	Appraisal																																																												
<b>Parameter</b>	<b>Results<sup>15</sup></b>	<b>HR<sup>16</sup></b>	<b>p value</b>																																																												
PFS <sup>3</sup>	5.6 - 7.3																																																														
OS <sup>5</sup>	62.0 - 67.7																																																														
<div style="border: 1px solid black; border-radius: 50%; padding: 2px; display: inline-block;">EU Approval 2019</div>																																																															
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;"></td> <td style="text-align: center;">5</td> <td style="text-align: center;">4</td> <td style="text-align: center;">3b</td> <td style="text-align: center;">3a</td> <td style="text-align: center;">2c</td> <td style="text-align: center;">2b</td> <td style="text-align: center;">2a</td> <td style="text-align: center;">1b</td> <td style="text-align: center;">1a</td> </tr> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="4"></td> <td style="text-align: center;">1</td> <td style="text-align: center;">2</td> <td style="text-align: center;">3</td> <td style="text-align: center;">4</td> <td style="text-align: center;">5</td> <td></td> </tr> <tr> <td colspan="4">Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="4"></td> <td style="text-align: center;">■</td> <td style="text-align: center;">■</td> <td colspan="4"></td> </tr> <tr> <td colspan="4"></td> <td style="text-align: center;">curative</td> <td style="text-align: center;">non-curative</td> <td colspan="4"></td> </tr> </table>					5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)														1	2	3	4	5		Clinical benefit (ESMO MCBS)														■	■									curative	non-curative				
	5	4	3b	3a	2c	2b	2a	1b	1a																																																						
Evidence (LoE)																																																															
				1	2	3	4	5																																																							
Clinical benefit (ESMO MCBS)																																																															
				■	■																																																										
				curative	non-curative																																																										
<b>Patients</b> ALK+, previously treated with ≥2 ALKi <b>Trial</b> Phase 2 <b>Randomisation</b> - : - <b>N<sup>1</sup></b> 111 <b>New Therapy</b> Lorlatinib <b>Control</b> <b>Publication</b> DOI:10.1016/S1470-2045(18)30649-1 DOI:10.1200/JCO.2018.78.7994		<b>Additional benefit (G-BA)</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"></td> <td style="text-align: center;">lower</td> <td style="text-align: center;">proven</td> <td style="text-align: center;">not quantifiable</td> <td style="text-align: center;">not minor</td> <td style="text-align: center;">considerable</td> <td style="text-align: center;">major</td> </tr> <tr> <td>suitable for immunochemotherapy</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>not suitable for immunochemotherapy</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>			lower	proven	not quantifiable	not minor	considerable	major	suitable for immunochemotherapy							not suitable for immunochemotherapy																																													
	lower	proven	not quantifiable	not minor	considerable	major																																																									
suitable for immunochemotherapy																																																															
not suitable for immunochemotherapy																																																															

Legende:

<sup>1</sup> N - number of patients

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>15</sup> results for control, results for new therapy

<sup>16</sup> hazard ratio for new therapy